12:00 AM
 | 
Jul 31, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Isis preclinical data

ISIP said that treatment with its second generation (2'-methoxyethyl) antisense inhibitor of PTP-1B for 4 weeks produced a significant and dose-dependent reduction in...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >